A Phase 2 Exploratory, Multicenter, Open-Label Trial To Determine The Safety And Preliminary Clinical Activity Of Gen1046 In Combination With Anticancer Agents In Subjects With Advanced Endometrial Cancer
Posted Date: Apr 25, 2024
- Investigator: Amanda Jackson
- Specialties: Cancer, Gynecologic Oncology
- Type of Study: Drug
The goal of this clinical study is to learn about the bispecific antibody, acasunlimab (also known as GEN1046) in combination with the cancer drug pembrolizumab for treatment of participants with incurable endometrial cancer (cancer of the womb).
Criteria:
Null
Keywords:
Cancer, Endometrial
For More Information:
Jessice Mullins
NULL
cancer@uchealth.com